Described as a clinical-histopathological definition in 1980, nonalcoholic steatohepatitis (NASH) [1], now renamed metabolic dysfunction-associated steatohepatitis (MASH) [2], has remained a neglected area for drug development for decades
Emphasize bland, low-fat, easy-to-digest foods during any adjustment windows
PlexusDx serves all 50 states, requires no insurance or membership, and accepts HSA/FSA funds for medication and testing
The best option for overweight people who would like to lose weight and manage their blood sugar at the same time is tirzepatide
Further research should explore the roles that diet and exercise play in the success of these medications, she added.
Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis